Milestone Pharmaceuticals (MIST) EBT (2018 - 2022)

Milestone Pharmaceuticals (MIST) has reported EBT for 5 consecutive years, with -$14.6 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, EBT fell 2.33% year-over-year to -$14.6 million; the trailing twelve-month figure through Sep 2022 stood at -$62.3 million (down 79.91% YoY), and the FY2021 full-year result was -$42.9 million, up 14.27% from the prior year.
• EBT advanced to -$14.6 million in Q3 2022 per MIST's latest filing, from -$16.6 million in the prior quarter.
• Across five years, EBT topped out at $770000.0 in Q2 2021 and bottomed at -$18.3 million in Q4 2019.
• Historically, EBT has averaged -$11.2 million across 5 years, with a median of -$12.7 million in 2019.
• The sharpest annual moves came in 2021 and 2022: EBT jumped 105.93% in 2021, then slumped 2262.08% in 2022.
• Over 5 years, EBT stood at -$9.7 million in 2018, then plunged by 89.31% to -$18.3 million in 2019, then soared by 52.62% to -$8.7 million in 2020, then tumbled by 94.83% to -$16.9 million in 2021, then rose by 13.79% to -$14.6 million in 2022.
• According to Business Quant data, EBT over the past three periods registered -$14.6 million, -$16.6 million, and -$16.9 million for Q3 2022, Q2 2022, and Q4 2021 respectively.